TABLE IA.
Systematic review key questions
| Topic | Key question |
|---|---|
| Feno | What is the diagnostic accuracy of Feno measurement(s) for making the diagnosis of asthma in individuals aged 5 y and older? |
| What is the clinical utility of Feno measurements in monitoring disease activity and asthma outcomes in individuals with asthma aged 5 y and older? | |
| What is the clinical utility of Feno measurements to select medication options (including steroids) for individuals aged 5 y and older? | |
| What is the clinical utility of Feno measurements to monitor response to treatment in individuals aged 5 y and older? | |
| In children aged 0–4 years with recurrent wheezing, how accurate is Feno testing in predicting the future development of asthma at age 5 y and above? | |
| Allergen mitigation | Among individuals with asthma, what is the effectiveness of interventions to reduce or remove exposures to indoor inhalant allergens on asthma control, exacerbations, quality of life, and other relevant outcomes? |
| ICS | What is the comparative effectiveness of intermittent ICS compared to no treatment, pharmacologic therapy, or nonpharmacologic therapy in children aged 0–4 y with recurrent wheezing? |
| What is the comparative effectiveness of intermittent ICS compared to ICS controller therapy in individuals 5 y and older with persistent asthma? | |
| What is the comparative effectiveness of ICS with LABA used as both controller and quick-relief therapy compared to ICS with or without LABA used as controller therapy in individuals 5 y and older with persistent asthma? | |
| LAMA | What is the comparative effectiveness of LAMA compared to other controller therapy as add-on to ICS in individuals aged 12 y and older with uncontrolled, persistent asthma? |
| What is the comparative effectiveness of LAMA as add-on to ICS controller therapy compared to placebo or increased ICS dose in individuals aged 12 y and older with uncontrolled, persistent asthma? | |
| What is the comparative effectiveness of LAMA as add-on to ICS-LABA compared to ICS-LABA as controller therapy in individuals aged 12 y and older with uncontrolled, persistent asthma? | |
| Immunotherapy | What is the evidence for the efficacy of SCIT in the treatment of asthma? |
| What is the evidence for the safety of SCIT in the treatment of asthma? | |
| What is the evidence for the efficacy of SLIT, in tablet and aqueous form, for the treatment of asthma? | |
| What is the evidence for the safety of SLIT, in tablet and aqueous form, for the treatment of asthma? | |
| BT | What are the benefits and harms of using BT in addition to standard treatment for the treatment of individuals aged 18 y and older with asthma? |